• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2012 Product Image

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2012

  • Published: October 2012
  • 281 pages
  • Global Markets Direct

Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer (Renal Cell Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer (Renal Cell Cancer). Kidney Cancer (Renal Cell Cancer) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Kidney Cancer (Renal Cell Cancer).
- A review READ MORE >

2
List of Tables 10
List of Figures 14
Introduction 15
REPORT COVERAGE 15
Kidney Cancer (Renal Cell Cancer) Overview 16
Therapeutics Development 17
An Overview of Pipeline Products for Kidney Cancer (Renal Cell Cancer) 17
Kidney Cancer (Renal Cell Cancer) Therapeutics under Development by Companies 19
Kidney Cancer (Renal Cell Cancer) Therapeutics under Investigation by Universities/Institutes 26
Late Stage Products 37
Comparative Analysis 37
Mid Clinical Stage Products 38
Comparative Analysis 38
Early Clinical Stage Products 39
Comparative Analysis 39
Discovery and Pre-Clinical Stage Products 40
Comparative Analysis 40
Kidney Cancer (Renal Cell Cancer) Therapeutics – Products under Development by Companies 41
Kidney Cancer (Renal Cell Cancer) Therapeutics – Products under Investigation by Universities/Institutes 50
Companies Involved in Kidney Cancer (Renal Cell Cancer) Therapeutics Development 71
Bristol-Myers Squibb Company 71
Boehringer Ingelheim GmbH 72
Kyowa Hakko Kirin Co., Ltd. 73
Abbott Laboratories 74
Amgen Inc. 75
AstraZeneca PLC 76
Eli Lilly and Company 77
GlaxoSmithKline plc 78
Seattle Genetics, Inc. 79
Genentech, Inc. 80
Antigenics, Inc. 81
Inovio Biomedical Corporation 82
Bavarian Nordic A/S 83
Light Sciences Oncology, Inc. 84
Amorfix Life Sciences Ltd. 85
Celltrion, Inc. 86
Novartis AG 87
ImClone Systems Incorporated 88
Astellas Pharma Inc. 89
Ono Pharmaceutical Co., Ltd. 90
OSI Pharmaceuticals, Inc. 91
Pfizer Inc. 92
Taiho Pharmaceutical Co., Ltd. 93
Exelixis, Inc. 94
Alfacell Corporation 95
Onyx Pharmaceuticals, Inc. 96
Bayer AG 97
MannKind Corporation 98
Hemispherx Biopharma, Inc. 99
Celldex Therapeutics, Inc. 100
Active Biotech AB 101
AEterna Zentaris Inc. 102
Lorus Therapeutics Inc 103
Bionomics Limited 104
Northwest Biotherapeutics, Inc. 105
Cleveland BioLabs, Inc. 106
Allos Therapeutics, Inc 107
Flamel Technologies S.A. 108
Dendreon Corporation 109
Green Cross Corporation 110
MOLOGEN AG 111
Innocell Corporation 112
OncoTherapy Science, Inc. 113
Threshold Pharmaceuticals, Inc. 114
Rexahn Pharmaceuticals, Inc. 115
Asan Medical Center 116
Debiopharm Group 117
Antisense Pharma GmbH 118
Wilex AG 119
Chipscreen Biosciences Ltd 120
Bionucleon Srl 121
Acceleron Pharma, Inc. 122
immatics biotechnologies GmbH 123
Curacyte AG 124
Argos Therapeutics, Inc. 125
Cytheris SA 126
Altor BioScience Corporation 127
GenSpera, Inc. 128
Cerulean Pharma, Inc. 129
Gene Signal International SA. 130
MacroGenics, Inc. 131
Neotropix, Inc. 132
Deciphera Pharmaceuticals, LLC 133
MSM Protein Technologies, Inc. 134
Jennerex Biotherapeutics, Inc. 135
Endocyte, Inc. 136
Advenchen Laboratories, LLC 137
Pharminox Limited 138
Immutep S.A. 139
Esperance Pharmaceuticals, Inc. 140
Welichem Biotech Inc. 141
Vaccinogen, Inc. 142
Tigris Pharmaceuticals, Inc. 143
TRACON Pharmaceuticals, Inc. 144
KAHR medical Ltd. 145
Pierre Fabre Medicament 146
Advanced Cancer Therapeutics 147
Anaphore, Inc. 148
n.v. BRUCELLS s.a. 149
Medical Enzymes AG 150
IkerChem S.L. 151
Ampio Pharmaceuticals, Inc. 152
Kidney Cancer (Renal Cell Cancer) – Therapeutics Assessment 153
Assessment by Monotherapy Products 153
Assessment by Combination Products 154
Assessment by Route of Administration 155
Assessment by Molecule Type 157
Drug Profiles 159
sorafenib tosylate - Drug Profile 159
Product Description 159
Mechanism of Action 159
R&D Progress 159
Inlyta - Drug Profile 161
Product Description 161
Mechanism of Action 161
R&D Progress 161
sunitinib malate - Drug Profile 163
Product Description 163
Mechanism of Action 163
R&D Progress 163
naptumomab - Drug Profile 165
Product Description 165
Mechanism of Action 165
R&D Progress 165
IMA-901 - Drug Profile 166
Product Description 166
Mechanism of Action 166
R&D Progress 166
AGS-003 - Drug Profile 167
Product Description 167
Mechanism of Action 167
R&D Progress 167
tivozanib - Drug Profile 169
Product Description 169
Mechanism of Action 169
R&D Progress 169
tivozanib - Drug Profile 171
Product Description 171
Mechanism of Action 171
R&D Progress 171
girentuximab - Drug Profile 173
Product Description 173
Mechanism of Action 173
R&D Progress 173
dovitinib lactate - Drug Profile 175
Product Description 175
Mechanism of Action 175
R&D Progress 175
aldesleukin - Drug Profile 177
Product Description 177
Mechanism of Action 177
R&D Progress 177
Aldesleukin + Recombinant Interferon Alfa + Fluorouracil - Drug Profile 178
Product Description 178
Mechanism of Action 178
R&D Progress 178
Torisel + Bevacizumab - Drug Profile 180
Product Description 180
Mechanism of Action 180
R&D Progress 180
Gemcitabine + Cisplatin + Bevacizumab - Drug Profile 181
Product Description 181
Mechanism of Action 181
R&D Progress 181
Interferon Alfa-2B + Bevacizumab - Drug Profile 182
Product Description 182
Mechanism of Action 182
R&D Progress 182
interferon alfa-2a - Drug Profile 183
Product Description 183
Mechanism of Action 183
R&D Progress 183
sorafenib tosylate - Drug Profile 184
Product Description 184
Mechanism of Action 184
R&D Progress 184
sunitinib malate - Drug Profile 186
Product Description 186
Mechanism of Action 186
R&D Progress 186
sorafenib tosylate - Drug Profile 187
Product Description 187
Mechanism of Action 187
R&D Progress 187
Dactinomycin + Doxorubicin + Vincristine - Drug Profile 189
Product Description 189
Mechanism of Action 189
R&D Progress 189
Dactinomycin + Carboplatin + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Vincristine Sulfate - Drug Profile 216
Product Description 216
Mechanism of Action 216
R&D Progress 217
Gemcitabine + Cisplatin + Carboplatin - Drug Profile 219
Product Description 219
Mechanism of Action 219
R&D Progress 219
doxorubicin - Drug Profile 220
Product Description 220
Mechanism of Action 220
R&D Progress 220
Gemcitabine + Cisplatin - Drug Profile 221
Product Description 221
Mechanism of Action 221
R&D Progress 221
sunitinib malate - Drug Profile 223
Product Description 223
Mechanism of Action 223
R&D Progress 223
thiotepa - Drug Profile 225
Product Description 225
Mechanism of Action 225
R&D Progress 225
sunitinib malate - Drug Profile 226
Product Description 226
Mechanism of Action 226
R&D Progress 226
R-100 - Drug Profile 227
Product Description 227
Mechanism of Action 227
R&D Progress 227
Kidney Cancer (Renal Cell Cancer) Therapeutics – Drug Profile Updates 228
Kidney Cancer (Renal Cell Cancer) Therapeutics – Discontinued Products 243
Kidney Cancer (Renal Cell Cancer) Therapeutics - Dormant Products 247
Kidney Cancer (Renal Cell Cancer) – Product Development Milestones 271
Featured News & Press Releases 271
Oct 01, 2012: AVEO And Astellas Announce Presentation Of New Data On Phase III TIVO-1 Trial Of Tivozanib At ESMO 2012 Congress 271
Sep 28, 2012: Aveo And Astellas Pharma Announce Submission Of New Drug Application For Tivozanib For Treatment Of Advanced Renal Cell Carcinoma 273
Sep 21, 2012: CHMP Adopts Positive Opinion For Novartis's Votubia Tablets To Treat Patients With Non-Cancerous Kidney Tumors Associated With TSC 273
Sep 17, 2012: Indian Appeals Body Dismisses Bayer’s Plea For Stay On Natco's Generic Nexavar 274
Sep 06, 2012: IPAB Concludes Hearing On Bayer’s Appeal Against Compulsory Licensing Of Cancer Drug Nexavar 275
Sep 04, 2012: Pfizer Receives EU Marketing Authorization For Inlyta 275
Aug 24, 2012: Seattle Genetics Initiates Phase Ib Trial Of SGN-75 In Combination With Everolimus For Patients With Renal Cell Carcinoma 276
Aug 10, 2012: Pfizer Reports Results From Phase III Study Of Torisel In Combination With Bevacizumab In Advanced Renal Cell Carcinoma 276
Jul 30, 2012: Agennix Announces Notice Of Allowance For US Patent Application Covering Use Of Talactoferrin Alfa To Treat Lung Cancer And Renal Cancer In Combination With Other Treatments 277
Jul 29, 2012: immatics Announces Publication Of IMA901 Cancer Vaccine Data In Nature Medicine 278
Appendix 280
Methodology 280
Coverage 280
Secondary Research 280
Primary Research 280
Expert Panel Validation 280
Contact Us 281
Disclaimer 281

List of Tables
Number of Products Under Development for Kidney Cancer (Renal Cell Cancer), H2 2012 17
Products under Development for Kidney Cancer (Renal Cell Cancer) – Comparative Analysis, H2 2012 18
Number of Products under Development by Companies, H2 2012 20
Number of Products under Development by Companies, H2 2012 (Contd..1) 21
Number of Products under Development by Companies, H2 2012 (Contd..2) 22
Number of Products under Development by Companies, H2 2012 (Contd..3) 23
Number of Products under Development by Companies, H2 2012 (Contd..4) 24
Number of Products under Development by Companies, H2 2012 (Contd..5) 25
Number of Products under Investigation by Universities/Institutes, H2 2012 27
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 36
Comparative Analysis by Late Stage Development, H2 2012 37
Comparative Analysis by Mid Clinical Stage Development, H2 2012 38
Comparative Analysis by Early Clinical Stage Development, H2 2012 39
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 40
Products under Development by Companies, H2 2012 41
Products under Development by Companies, H2 2012 (Contd..1) 42
Products under Development by Companies, H2 2012 (Contd..2) 43
Products under Development by Companies, H2 2012 (Contd..3) 44
Products under Development by Companies, H2 2012 (Contd..4) 45
Products under Development by Companies, H2 2012 (Contd..5) 46
Products under Development by Companies, H2 2012 (Contd..6) 47
Products under Development by Companies, H2 2012 (Contd..7) 48
Products under Development by Companies, H2 2012 (Contd..8) 49
Products under Investigation by Universities/Institutes, H2 2012 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 68
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 70
Bristol-Myers Squibb Company, H2 2012 71
Boehringer Ingelheim GmbH, H2 2012 72
Kyowa Hakko Kirin Co., Ltd., H2 2012 73
Abbott Laboratories, H2 2012 74
Amgen Inc., H2 2012 75
AstraZeneca PLC, H2 2012 76
Eli Lilly and Company, H2 2012 77
GlaxoSmithKline plc, H2 2012 78
Seattle Genetics, Inc., H2 2012 79
Genentech, Inc., H2 2012 80
Antigenics, Inc., H2 2012 81
Inovio Biomedical Corporation, H2 2012 82
Bavarian Nordic A/S, H2 2012 83
Light Sciences Oncology, Inc., H2 2012 84
Amorfix Life Sciences Ltd., H2 2012 85
Celltrion, Inc., H2 2012 86
Novartis AG, H2 2012 87
ImClone Systems Incorporated, H2 2012 88
Astellas Pharma Inc., H2 2012 89
Ono Pharmaceutical Co., Ltd., H2 2012 90
OSI Pharmaceuticals, Inc., H2 2012 91
Pfizer Inc., H2 2012 92
Taiho Pharmaceutical Co., Ltd., H2 2012 93
Exelixis, Inc., H2 2012 94
Alfacell Corporation, H2 2012 95
Onyx Pharmaceuticals, Inc., H2 2012 96
Bayer AG, H2 2012 97
MannKind Corporation, H2 2012 98
Hemispherx Biopharma, Inc., H2 2012 99
Celldex Therapeutics, Inc., H2 2012 100
Active Biotech AB, H2 2012 101
AEterna Zentaris Inc., H2 2012 102
Lorus Therapeutics Inc, H2 2012 103
Bionomics Limited, H2 2012 104
Northwest Biotherapeutics, Inc., H2 2012 105
Cleveland BioLabs, Inc., H2 2012 106
Allos Therapeutics, Inc, H2 2012 107
Flamel Technologies S.A., H2 2012 108
Dendreon Corporation, H2 2012 109
Green Cross Corporation, H2 2012 110
MOLOGEN AG, H2 2012 111
Innocell Corporation, H2 2012 112
OncoTherapy Science, Inc., H2 2012 113
Threshold Pharmaceuticals, Inc., H2 2012 114
Rexahn Pharmaceuticals, Inc., H2 2012 115
Asan Medical Center, H2 2012 116
Debiopharm Group, H2 2012 117
Antisense Pharma GmbH, H2 2012 118
Wilex AG, H2 2012 119
Chipscreen Biosciences Ltd, H2 2012 120
Bionucleon Srl, H2 2012 121
Acceleron Pharma, Inc., H2 2012 122
immatics biotechnologies GmbH, H2 2012 123
Curacyte AG, H2 2012 124
Argos Therapeutics, Inc., H2 2012 125
Cytheris SA, H2 2012 126
Altor BioScience Corporation, H2 2012 127
GenSpera, Inc., H2 2012 128
Cerulean Pharma, Inc., H2 2012 129
Gene Signal International SA., H2 2012 130
MacroGenics, Inc., H2 2012 131
Neotropix, Inc., H2 2012 132
Deciphera Pharmaceuticals, LLC, H2 2012 133
MSM Protein Technologies, Inc., H2 2012 134
Jennerex Biotherapeutics, Inc., H2 2012 135
Endocyte, Inc., H2 2012 136
Advenchen Laboratories, LLC, H2 2012 137
Pharminox Limited, H2 2012 138
Immutep S.A., H2 2012 139
Esperance Pharmaceuticals, Inc., H2 2012 140
Welichem Biotech Inc., H2 2012 141
Vaccinogen, Inc., H2 2012 142
Tigris Pharmaceuticals, Inc., H2 2012 143
TRACON Pharmaceuticals, Inc., H2 2012 144
KAHR medical Ltd., H2 2012 145
Pierre Fabre Medicament, H2 2012 146
Advanced Cancer Therapeutics, H2 2012 147
Anaphore, Inc., H2 2012 148
n.v. BRUCELLS s.a., H2 2012 149
Medical Enzymes AG, H2 2012 150
IkerChem S.L., H2 2012 151
Ampio Pharmaceuticals, Inc., H2 2012 152
Assessment by Monotherapy Products, H2 2012 153
Assessment by Combination Products, H2 2012 154
Assessment by Stage and Route of Administration, H2 2012 156
Assessment by Stage and Molecule Type, H2 2012 158
Kidney Cancer (Renal Cell Cancer) Therapeutics – Drug Profile Updates 228
Kidney Cancer (Renal Cell Cancer) Therapeutics – Discontinued Products 243
Kidney Cancer (Renal Cell Cancer) Therapeutics – Discontinued Products (Contd..1) 244
Kidney Cancer (Renal Cell Cancer) Therapeutics – Discontinued Products (Contd..2) 245
Kidney Cancer (Renal Cell Cancer) Therapeutics – Discontinued Products (Contd..3) 246
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products 247
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..1) 248
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..2) 249
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..3) 250
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..4) 251
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..5) 252
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..6) 253
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..7) 254
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..8) 255
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..9) 256
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..10) 257
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..11) 258
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..12) 259
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..13) 260
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..14) 261
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..15) 262
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..16) 263
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..17) 264
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..18) 265
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..19) 266
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..20) 267
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..21) 268
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..22) 269
Kidney Cancer (Renal Cell Cancer) Therapeutics – Dormant Products (Contd..23) 270

List of Figures
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2012 17
Products under Development for Kidney Cancer (Renal Cell Cancer) – Comparative Analysis, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 26
Late Stage Products, H2 2012 37
Mid Clinical Stage Products, H2 2012 38
Early Clinical Stage Products, H2 2012 39
Discovery and Pre-Clinical Stage Products, H2 2012 40
Assessment by Monotherapy Products, H2 2012 153
Assessment by Combination Products, H2 2012 154
Assessment by Route of Administration, H2 2012 155
Assessment by Stage and Route of Administration, H2 2012 156
Assessment by Molecule Type, H2 2012 157
Assessment by Stage and Molecule Type, H2 2012 158

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos